Zobrazeno 1 - 10
of 541
pro vyhledávání: '"Kan, Yonemori"'
Autor:
Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai, Naohito Yamamoto, Chi-Feng Chung, Yen-Shen Lu, Dwan-Ying Chang, Joohyuk Sohn, Gun Min Kim, Kyung-Hun Lee, Soo-Chin Lee, Tsutomu Iwasa, Hiroji Iwata, Kenichi Watanabe, Kyung Hae Jung, Yuko Tanabe, Seok Yun Kang, Hiroyuki Yasojima, Kenjiro Aogi, Eriko Tokunaga, Sung Hoon Sim, Yoon Sim Yap, Koji Matsumoto, Ling-Ming Tseng, Yoshiko Umeyama, Kazuki Sudo, Yuki Kojima, Tomomi Hata, Aya Kuchiba, Taro Shibata, Kenichi Nakamura, Yasuhiro Fujiwara, Kenji Tamura, Kan Yonemori
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-10 (2024)
Abstract Palbociclib combined with endocrine therapy is approved for treating patients with hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer; however, data on palbociclib combined with t
Externí odkaz:
https://doaj.org/article/3cba658e7441401e9b9e50ad16a29171
Autor:
Risako Ozawa, Tadaaki Nishikawa, Kasumi Yamamoto, Tatsunori Shimoi, Mitsuya Ishikawa, Tomoyasu Kato, Kan Yonemori
Publikováno v:
Gynecologic Oncology Reports, Vol 55, Iss , Pp 101479- (2024)
Lenvatinib plus pembrolizumab (LP) therapy is currently used in patients with advanced or recurrent endometrial cancer. However, patients with uterine carcinosarcoma (UCS) were not included in the KEYNOTE-775, and the efficacy of LP therapy for patie
Externí odkaz:
https://doaj.org/article/7000a99a76ee49c3a0ab69bfa248053a
Autor:
Kosei Hasegawa, Shunji Takahashi, Kimio Ushijima, Masao Okadome, Kan Yonemori, Harushige Yokota, Ignace Vergote, Bradley J. Monk, Krishnansu S. Tewari, Keiichi Fujiwara, Jingjin Li, Shaheda Jamil, Anne Paccaly, Kazuhiro Takehara, Tomoka Usami, Yoichi Aoki, Nao Suzuki, Yoichi Kobayashi, Yoshio Yoshida, Hidemichi Watari, Frank Seebach, Israel Lowy, Melissa Mathias, Matthew G. Fury, Ana Oaknin
Publikováno v:
Cancer Medicine, Vol 13, Iss 18, Pp n/a-n/a (2024)
Abstract Background In the phase 3 EMPOWER‐Cervical 1/GOG‐3016/ENGOT‐cx9 study, cemiplimab significantly improved overall survival (OS) versus chemotherapy for patients with recurrent or metastatic cervical cancer who progressed after first‐l
Externí odkaz:
https://doaj.org/article/143c8c3d40d4478d8742c856b4915c25
Autor:
Yasutoshi Kuboki, Takafumi Koyama, Nobuaki Matsubara, Yoichi Naito, Shunsuke Kondo, Kenichi Harano, Kan Yonemori, Kiyotaka Yoh, Yuan Gu, Tetsuya Mita, Xuejun Chen, Eiji Ueda, Noboru Yamamoto, Toshihiko Doi, Toshio Shimizu
Publikováno v:
Cancer Medicine, Vol 13, Iss 8, Pp n/a-n/a (2024)
Abstract Background Retifanlimab is a humanized monoclonal antibody targeting programmed death protein‐1, and INCB001158 is an oral arginase inhibitor. This phase Ib study investigated retifanlimab, INCB001158, and their combination in Japanese pat
Externí odkaz:
https://doaj.org/article/054b73aa0e9c4d059dd35a08e6fa57cd
Autor:
Hisaki Aiba, Yuki Kojima, Tatsunori Shimoi, Kazuki Sudo, Shu Yazaki, Toru Imai, Akihiko Yoshida, Shintaro Iwata, Eisuke Kobayashi, Akira Kawai, Ayumu Arakawa, Chitose Ogawa, Hiroaki Kimura, Kan Yonemori
Publikováno v:
Cancer Medicine, Vol 13, Iss 5, Pp n/a-n/a (2024)
Abstract Background Skeletal‐related events (SREs), including the pathological fracture, surgical treatment or radiation of bone lesions, malignant spinal cord compression, hypercalcemia, are important considerations when managing metastatic bone t
Externí odkaz:
https://doaj.org/article/944f410141194ef9b9e356c0368b621f
Autor:
Junki Mizusawa, Hioryuki Sato, Larry V. Rubinstein, Takeo Fujiwara, Kan Yonemori, Akihiro Hirakawa
Publikováno v:
Cancer Medicine, Vol 12, Iss 17, Pp 18098-18109 (2023)
Abstract Background Racial differences have been reported in toxicity outcomes for anticancer drug treatments. However, these observations were often from studies with small sample sizes, and many only reported the maximum grade of toxicity and no lo
Externí odkaz:
https://doaj.org/article/ff7ae06b934e4ed69832dca2572283c4
Autor:
Masaki Uchihara, Akiyo Tanabe, Yuki Kojima, Tatsunori Shimoi, Akiko Miyagi Maeshima, Kotaro Umamoto, Akihiko Shimomura, Chikako Shimizu, Yuto Yamazaki, Eijiro Nakamura, Yoshiyuki Matsui, Nobuyuki Takemura, Hideyo Miyazaki, Kazuki Sudo, Kan Yonemori, Hiroshi Kajio
Publikováno v:
Cancers, Vol 16, Iss 12, p 2191 (2024)
Metastatic pheochromocytomas and paragangliomas (PPGLs) are rare endocrine malignancies with limited effective treatment options. The association between the tumor microenvironment (TME) with somatostatin receptor 2 (SSTR2) and hypoxia-induced factor
Externí odkaz:
https://doaj.org/article/29fa8a783fc04db89f4143b1f3411860
Autor:
Kan Yonemori1 kyonemor@ncc.go.jp, Keiichi Fujiwara2, Kosei Hasegawa2, Mayu Yunokawa3, Kimio Ushijima4, Shiro Suzuki5, Ayumi Shikama6, Shinichiro Minobe7, Tomoka Usami8, Jae-Weon Kim9, Byoung-Gie Kim10, Peng-Hui Wang11, Ting-Chang Chang12, Keiko Yamamoto13, Shirong Han14, McKenzie, Jodi15, Orlowski, Robert J.16, Takuma Miura17, Makker, Vicky18, Yong Man Kim19
Publikováno v:
Journal of Gynecologic Oncology. Mar2024, Vol. 35 Issue 2, p1-13. 13p.
Autor:
Ryota Tashiro, Hitoshi Kawazoe, Kanako Mamishin, Keisuke Seto, Ryoko Udagawa, Yoshimasa Saito, Hironobu Hashimoto, Tatsunori Shimoi, Kan Yonemori, Masahito Yonemura, Hiroyuki Terakado, Takahiro Nishimura, Toshikatsu Kawasaki, Tetsuya Furukawa, Tomonori Nakamura
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract The standard treatment for platinum-sensitive relapsed ovarian cancer (PSROC) is platinum-based chemotherapy followed by olaparib monotherapy. A retrospective study was conducted to identify factors affecting the survival of patients with PS
Externí odkaz:
https://doaj.org/article/23d39bf62fc4468f8b2f7a2bcc990961
Autor:
Sho Watanabe, Tatsunori Shimoi, Tadaaki Nishikawa, Asuka Kawachi, Hitomi Sumiyoshi Okuma, Momoko Tokura, Shu Yazaki, Chiharu Mizoguchi, Motoko Arakaki, Ayumi Saito, Shosuke Kita, Kasumi Yamamoto, Yuki Kojima, Kazuki Sudo, Emi Noguchi, Akihiko Yoshida, Akira Kawai, Yasuhiro Fujiwara, Kan Yonemori
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Prognostic value of hematologic indices and their association with the tumor microenvironment (TME) remain unclear in advanced soft tissue sarcoma (STS). We aimed to evaluate their prognostic value and correlation with the TME status in adva
Externí odkaz:
https://doaj.org/article/7169a5aae4cb428bbaf374a0faa34c96